{
  "pmcid": "12122560",
  "sha256": "c81e92ce7c842bb325d899c5e6e0a5646add71af5505b2cb5dd025cecf385686",
  "timestamp_utc": "2025-11-09T22:15:41.385046+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.168929515418505,
    "reading_ease": 28.46408443465492,
    "word_count": 227
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Gastrointestinal Motility Agents in Elective Colorectal Surgery"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults undergoing elective colorectal surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Interventions included prokinetics and laxatives, compared to placebo or standard ERAS care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy and safety of GI motility agents in this context."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was GI-2 recovery, defined as tolerance of solid diet and stool passage, measured within the first postoperative week."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods varied across studies."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Blinding was implemented for patients and outcome assessors."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "GI motility agents significantly accelerated GI-2 recovery (mean difference –1.01 days; 95% CI –1.29 to –0.73; p < 0.001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant differences were observed in safety outcomes, including anastomotic leak (OR 0.97; 95% CI 0.53 to 1.77), nasogastric tube reinsertion (OR 0.86; 95% CI 0.49 to 1.51), or readmission rates (OR 1.03; 95% CI 0.62 to 1.72)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD420250655358."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}